scholarly journals DETERMINATION OF DIAGNOSTIC ACCURACY OF BIOCHEMICAL PARAMETERS (CRP, LDH & FERRITIN) IN THE DIAGNOSIS OF COVID-19 IN SUSPECTED COVID CASES

2021 ◽  
Vol 71 (5) ◽  
pp. 1722-26
Author(s):  
Tayyaba Ashiq ◽  
Abdus Sattar ◽  
Nasir Uddin ◽  
Qamar Bashir ◽  
Sajida Shaheen ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Lactate Dehydrogenase ◽  
Diagnostic Accuracy ◽  
Biochemical Parameters ◽  
C Reactive Protein ◽  
Chain Reaction ◽  
Reactive Protein ◽  
Poor Predictor ◽  
Lactate Dehydrogenase C ◽  
Polymerase Chain

Objective: To determine the diagnostic accuracy of the Lactate Dehydrogenase, C-Reactive Protein and Ferritin in suspected patients of COVID-19. Study Design: Cross-sectional validation study. Place and Duration of Study: Pathology department of Combined Military Hospital Lahore in the month of May 2020. Methodology: We included 101 adult (>18 years) symptomatic suspected COVID-19 patients of both genders. Children, pregnant women and asymptomatic patients were excluded from study. Age, gender and results of Reverse Transcriptase Polymerase Chain Reaction, Lactate Dehydrogenase, C-Reactive Protein, ferritin were recorded. Results: Lactate Dehydrodenase had highest sensitivity (75%) with positive predictive value of 71.6% and diagnostic accuracy of 65.3% among three biochemical parameters studied. Receiver Operator Characteristic curve was studied. Area under curve of Lactate Dehydrogenase (AUC=0.65) and Ferritin (AUC=0.59) reflected their ability to prognosticate the presence of COVID19 disease. However, C-Reactive Protein (AUC=0.42) appeared to be a poor predictor of the disease. Conclusion: Raised serum Lactate Dehydrogenase (>490 U/L) and Ferritin (>152 ng/L) levels can be used to predict the Reverse Transcriptase Polymerase Chain Reaction positivity for COVID-19 in the population of suspected patients of COVID19. However, C-Reactive Protein is a poor predictor of COVID-19.

scholarly journals Uji Diagnostik C-Reactive Protein pada Pneumonia Bakteri Komunitas Anak

Sari Pediatri ◽  
2016 ◽  
Vol 17 (5) ◽  
pp. 391
Author(s):  
Ikhsan Marzony ◽  
Finny Fitry Yani ◽  
Efrida Efrida
Keyword(s):  
Polymerase Chain Reaction ◽  
C Reactive Protein ◽  
Chain Reaction ◽  
Cross Sectional ◽  
Reactive Protein ◽  
Polymerase Chain

Latar belakang. Polymerase chain reaction (PCR) merupakan teknik untuk menentukan agen penyebab pneumonia dengan sensitivitas dan spesifisitas yang tinggi, tetapi harganya mahal dan tidak tersedia di semua tempat. C-reactive protein (CRP) juga dapat digunakan untuk memprediksi infeksi bakteri dan memiliki keunggulan yang lain, yakni harganya yang murah dan hampir tersedia di semua laboratorium.Tujuan. Mengetahui sensitivitas, spesifisitas, nilai prediksi positif, dan nilai prediksi negatif CRP pada pneumonia bakteri komunitas anak.Metode. Penelitian cross sectional pada 62 subjek di Bagian Ilmu Kesehatan Anak RS. Dr. M. Djamil Padang dari Desember 2013 sampai Oktober 2014. Subjek dipilih dengan teknik konsekutif. Dilakukan uji CRP dan teknik PCR sebagai baku emas. Duapuluh tiga sampel diekslusi karena menderita penyakit jantung bawaan (7), sepsis (6), telah mendapatkan antibiotik (4), dan orang tua menolak pemeriksaan (6) sehingga total sampel menjadi 39 anak.Hasil. Sebagian besar subjek penelitian adalah laki-laki (59%) dan kelompok umur terbanyak 2-11 bulan (48,7%). Sensitivitas CRP dengan cut off point 8 mg/L adalah 51,6%, spesifisitas 75%, nilai prediksi positif 88,8%, nilai prediksi negatif 28,6%. Pada cut off point 10 mg/L, sensitivitas CRP adalah 41,9%, spesifisitas 87,5%, nilai prediksi positif 92,9%, nilai prediksi negatif 28%.Kesimpulan. C-reactive protein tidak dapat digunakan sebagai uji tapis terhadap pneumonia bakteri komunitas anak.

scholarly journals Assessment of Serum L-Ficolin Level as Inflammatory Marker and Its Correlation with Serum C-Reactive Protein, D-Dimer and Ferritin in a Sample of Iraqi COVID-19 Patients

2021 ◽  
Vol 23 (08) ◽  
pp. 107-116
Author(s):  
Layth Taha Abdulhussein ◽  
◽  
Dr. Mohammed Abdullatif ◽  
Dr. Aref Sami Malik ◽  
◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Reverse Transcriptase ◽  
Disease Stage ◽  
Viral Gene ◽  
Upper Respiratory Tract ◽  
C Reactive Protein ◽  
Chain Reaction ◽  
Reactive Protein ◽  
Polymerase Chain ◽  
D Dimer

Subject: At the end of December 2019, a COVID-19 outbreak was reported for the first time in Wuhan, China. Which quickly expanded throughout China, then to 209 nations across America, Europe, Australia, and Asia. More than 50,000 people have died and over one million individuals have been afflicted worldwide, with the number fast rising. COVID-19 has been combated in various ways around the world. The gold standard for COVID-19 diagnosis is real-time fluorescence quantitative reverse transcriptase polymerase chain reaction (reverse transcriptase-polymerase chain reaction, RT-PCR) and viral gene sequencing. Currently, nasopharyngeal swabs from the upper respiratory tract are the most commonly employed nucleic acid detection samples. Objective of the Study: To estimate the level of ficolin in covid-19 patient in moderate and severe disease stage determination (series measurement and follow up) and find the diagnostic tool to early detect the virus to minimize the severity of the disease and further complication. Correlation of serum L-ficolin concentrations with Serum C-Reactive Protein, D-Dimer and Ferritin also to find Prognostic value of L-ficolin will be studied by corelating the treatment outcomes over one month with the three initial L-ficolin level. Materials and Methods: Sixty-two patients will be involved in the study from both sex male and female and different age group (18-80 yr.), the basal level of ficolin will be measure at time of admission of patient (time zero), then further serial measurement will be done on day 7 of admission for precise ficolin monitoring. Results: This study shows elevation of serum L-Ficolin level in survival and non-survival group. Conclusion: The results showed significant negative correlation between L-ficolin levels with the duration of illness (r = -0.377, p =0.020), however there were no significant correlation between L-ficolin levels with other patient‟s parameters.

scholarly journals Experience with the use of siltuximab in patients with SARS-CoV-2 infection

2021 ◽  
Author(s):  
Fernanda Meira ◽  
Laia Albiach ◽  
Cristina Carbonell ◽  
José-Ángel Martín-Oterino ◽  
Mercedes Martín-Ordiales ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Nasopharyngeal Swab ◽  
C Reactive Protein ◽  
Median Dose ◽  
First Line ◽  
Chain Reaction ◽  
Positive Polymerase Chain Reaction ◽  
Reactive Protein ◽  
Polymerase Chain ◽  
Hospital Clinic

Objectives. The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that received siltuximab according to a protocol that aimed to early block the activity of IL-6 to avoid the progression of the inflammatory flare. Patients and methods. Retrospective review of the first 31 patients with SARS-CoV-2 treated with siltuximab, in Hospital Clinic of Barcelona or Hospital Universitario Salamanca, from March to April 2020 with positive polymerase-chain reaction (PCR) from a nasopharyngeal swab. Results. The cohort included 31 cases that received siltuximab with a median (IQR) age of 62 (56-71) and 71% were males. The most frequent comorbidity was hypertension (48%). The median dose of siltuximab was 800 mg ranging between 785 and 900 mg. 7 patients received siltuximab as a salvage therapy after one dose of tocilizumab. At the end of the study, a total of 26 (83.9) patients had been discharged alive and the mortality rate was 16.1% but only 1 out of 24 that received siltuximab as a first line option (4%). Conclusions. Siltuximab is a well-tolerated alternative to tocilizumab when administered as a first line option in patients with COVID-19 pneumonia within the first 10 days from symptoms onset and high C-reactive protein.

scholarly journals Respiratory and non-respiratory manifestations in children admitted with COVID 19 in Rio de Janeiro city, Brazil

2021 ◽  
Author(s):  
AR Araujo da Silva ◽  
CGB Fonseca ◽  
JLPS Miranda ◽  
BV Travassos ◽  
CR Baião ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Length Of Stay ◽  
Respiratory Symptoms ◽  
C Reactive Protein ◽  
Chain Reaction ◽  
Serological Tests ◽  
Main Symptom ◽  
Reactive Protein ◽  
Polymerase Chain ◽  
Janeiro City

AbstractIntroductionCOVID 19 is still a challenge in pediatrics due to variety of symptoms and different presentationsAimTo describe clinical, laboratorial and treatment of confirmed COVID-19 pediatric admitted in hospitals.MethodsA retrospective study was conducted in children (0-18 years), admitted between March and November 15, 2020, with confirmed COVID-19 by reverse transcription polymerase chain reaction or serological tests. Clinical data about symptoms, laboratorial exams and treatments were analysed. Patients were evaluated according predominant (PRS) or non-predominant respiratory symptoms (non-PRS)ResultsSixty-four patients were evaluated, being the median age 5.6 years. Forty-seven (73.4%) children were admitted with PRS and 17 (26.4%) with non-PRS. The main symptoms in the PRS group were fever in 74.5% of children and cough in 66%; and fever in 76.5% and edema/cavitary effusion in 29.4% in the non-PRS group. The median of C-reactive protein (in mg/dl) was 2.5 in the PRS group and 6.1 in the non-PRS group. Antibiotics were used in 85.1% of the PRS group and 94.1% of non-group. Comorbidity was present in 30/47 (63.8%) of PRS group and 8/17 (47.1%) of non-PRS group (p=0.22). Length of stay until 7 days in patients with comorbidity was present in 27/64 (42.1%) and more than 7 days in 11/64 (17.1%) (p= 0.2)ConclusionNon-PRS represented more than one quarter of admitted patients. Fever was the main symptom detected, elevated CRP was frequent and antibiotics were commonly prescribed. Comorbidity was found in both groups and his presence was not associated with a longer length of stay.

Diagnostic Accuracy of a Direct Panfungal Polymerase Chain Reaction Assay Performed on Stained Cytology Slides

2021 ◽  
pp. 030098582199156
Author(s):  
Alexandra N. Myers ◽  
Unity Jeffery ◽  
Zachary G. Seyler ◽  
Sara D. Lawhon ◽  
Aline Rodrigues Hoffmann
Keyword(s):  
Polymerase Chain Reaction ◽  
Diagnostic Accuracy ◽  
Molecular Techniques ◽  
Fungal Culture ◽  
Chain Reaction ◽  
Identification Of Fungi ◽  
Fungal Dna ◽  
Polymerase Chain ◽  
Panfungal Pcr ◽  
Pcr Targeting

Molecular techniques are increasingly being applied to stained cytology slides for the diagnosis of neoplastic and infectious diseases. Such techniques for the identification of fungi from stained cytology slides have not yet been evaluated. This study aimed to assess the diagnostic accuracy of direct (without nucleic acid isolation) panfungal polymerase chain reaction (PCR) followed by sequencing for identification of fungi and oomycetes on stained cytology slides from dogs, cats, horses, and other species. Thirty-six cases were identified with cytologically identifiable fungi/oomycetes and concurrent identification via fungal culture or immunoassay. Twenty-nine controls were identified with no cytologically or histologically visible organisms and a concurrent negative fungal culture. Direct PCR targeting the internal transcribed spacer region followed by sequencing was performed on one cytology slide from each case and control, and the sensitivity and specificity of the assay were calculated. The sensitivity of the panfungal PCR assay performed on stained cytology slides was 67% overall, 73% excluding cases with oomycetes, and 86% when considering only slides with abundant fungi. The specificity was 62%, which was attributed to amplification of fungal DNA from control slides with no visible fungus and negative culture results. Direct panfungal PCR is capable of providing genus- or species-level identification of fungi from stained cytology slides. Given the potential of panfungal PCR to amplify contaminant fungal DNA, this assay should be performed on slides with visible fungi and interpreted in conjunction with morphologic assessment by a clinical pathologist.

scholarly journals Missed Plasmodium falciparum and Plasmodium vivax Mixed Infections in Ethiopia Threaten Malaria Elimination

2021 ◽  
Author(s):  
Colleen M. Leonard ◽  
Hussein Mohammed ◽  
Mekonnen Tadesse ◽  
Jessica N. McCaffery ◽  
Doug Nace ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Plasmodium Falciparum ◽  
Lactate Dehydrogenase ◽  
Plasmodium Vivax ◽  
Therapeutic Efficacy ◽  
Dried Blood Spots ◽  
Mixed Infections ◽  
Efficacy Study ◽  
Chain Reaction ◽  
Polymerase Chain

Plasmodium falciparum and Plasmodium vivax are co-endemic in Ethiopia. This study investigated whether mixed infections were missed by microscopy from a 2017 therapeutic efficacy study at two health facilities in Ethiopia. All patients (N = 304) were initially classified as having single-species P. falciparum (n = 148 samples) or P. vivax infections (n = 156). Dried blood spots were tested for Plasmodium antigens by bead-based multiplex assay for pan-Plasmodium aldolase, pan-Plasmodium lactate dehydrogenase, P. vivax lactate dehydrogenase, and histidine-rich protein 2. Of 304 blood samples, 13 (4.3%) contained both P. falciparum and P. vivax antigens and were analyzed by polymerase chain reaction for species-specific DNA. Of these 13 samples, five were confirmed by polymerase chain reaction for P. falciparum/P. vivax co-infection. One sample, initially classified as P. vivax by microscopy, was found to only have Plasmodium ovale DNA. Plasmodium falciparum/P. vivax mixed infections can be missed by microscopy even in the context of a therapeutic efficacy study with multiple trained readers.

HRP2/3 mutation in recrudescent Plasmodium falciparum malaria case acquired in Ethiopia

2020 ◽  
Author(s):  
Shiraz Gefen-Halevi ◽  
Valentin Belinson ◽  
Uri Manor ◽  
Zeala Gazit ◽  
Gill Smollan ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Plasmodium Falciparum ◽  
Lactate Dehydrogenase ◽  
Falciparum Malaria ◽  
Malaria Case ◽  
Rapid Detection ◽  
Plasmodium Falciparum Malaria ◽  
Malaria Prophylaxis ◽  
Chain Reaction ◽  
Polymerase Chain

A 65-year-old Israeli working in Welkait, Ethiopia, not using malaria prophylaxis, developed fever. Malaria rapid detection test was consistent with non-falciparum malaria (plasmodium lactate dehydrogenase+/histidine-rich protein− [LDH+/HRP−]) but microscopy showed typical Plasmodium falciparum. HRP2/3 were negative by polymerase chain reaction. The patient suffered two recrudescence episodes following artemether–lumefantrine and atovaquone–proguanil treatments, and responded to mefloquine treatment.

Sign in / Sign up

Export Citation Format

Share Document